'Slow Money As Bad As No Money' – SMEs Struggle For Superbug Funds

 
• By Kevin Grogan

The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip. 

Charity
Biotechs chasing cash to fund AMR projects • Source: Shutterstock

More from Anti-infective

More from Therapy Areas